PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma
PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma
复制标题
DOI：
10.3109/10428194.2010.502584
复制
发表时间：
2010-09-01
影响因子：
2.6
通讯作者：
Yang, Shu-Jun
中科院分区：
文献类型：
--
作者：
Liu, Yan-Yan;Yao, Shu-Na;Yang, Shu-Jun
10号染色体上缺失的磷酸酶和张力蛋白同源基因(PTEN)和p53抑癌基因是人类癌症中最常见的失活或突变基因，它们的通路相互作用并以互补的方式相互作用。为了解它们在弥漫性大B细胞淋巴瘤(DLBCL)中的作用及相互关系，我们检测了62例DLBCL患者中它们的表达，并评价了它们的预后意义。结果显示，PTEN蛋白缺失23例(37.1%)，其缺失与PI3K/AKT通路的激活有关，与患者的临床预后无关。P53基因突变蛋白阳性30例(48.4%)，与预后相关。多因素分析结果显示，DLBCL患者生存期短与P53突变有关，而与PTEN缺失无关。PTEN状态对P53突变相关的不良生存率无影响。我们的结论是，PTEN的预后作用可能不如P53，P53突变蛋白应该被认为是DLBCL患者需要更积极治疗的预测因素。
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and P53 tumor suppressors are among the most commonly inactivated or mutated genes in human cancers, whose pathways cross-talk and interact in a complementary mode. In order to understand their roles and relationship in diffuse large B-cell lymphoma (DLBCL), we examined their expression and evaluated their prognostic significance in 62 patients with DLBCL treated with standard chemotherapy. Results showed that PTEN protein was lost in 23 (37.1%) cases, and the loss was associated with the activation of PI3K/AKT pathway, but was not associated with patient's clinical outcome. P53 mutation protein was detected in 30 (48.4%) cases and was associated with poor survival. Results of multivariate analysis showed that P53 mutation but not PTEN loss is associated with short survival in patients with DLBCL. PTEN status has no effect on P53 mutation-associated poor survival. We conclude that PTEN may play less prognostic role than P53 and that P53 mutation protein should be considered as a predictive factor of the need for a more aggressive therapy in patients with DLBCL who express P53.